Downstream signalling of the disease‐associated mutations on GPR56/ADGRG1
Basic & Clinical Pharmacology & Toxicology · 2023
DOI: 10.1111/bcpt.13873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Orkun Cevheroğlu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Institute, Ankara University, Ankara, Türkiye. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, GTP-Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştirma Kurumu, The Scientific and Technological Council of Turkey, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
GPR56/ADGRG1 is an adhesion G protein‐coupled receptor (GPCR) and mutations on this receptor cause cortical malformation due to the over‐migration of neural progenitor cells on brain surface. At pial surface, GPR56 interacts with collagen III, induces Rho‐dependent activation through Gα 12/13 and inhibits the neuronal migration. In human glioma cells, GPR56 inhibits cell migration through Gα q/11 ‐dependent Rho pathway. GPR56‐tetraspanin complex is known to couple Gα q/11 . GPR56 is an aGPCR that couples with various G proteins and signals through different downstream pathways. In this study, bilateral frontoparietal polymicrogyria ( BFPP ) mutants disrupting GPR56 function but remaining to be expressed on plasma membrane were used to study receptor signalling through Gα 12 , Gα 13 and Gα 11 with BRET biosensors. GPR56 showed coupling with all three G proteins and activated heterotrimeric G protein signalling upon stimulation with Stachel peptide. However, BFPP mutants showed different signalling defects for each G protein indicative of distinct activation and signalling properties of GPR56 for Gα 12 , Gα 13 or Gα 11 . β‐arrestin recruitment was also investigated following the activation of GPR56 with Stachel peptide using BRET biosensors. N‐terminally truncated GPR56 showed enhanced β‐arrestin recruitment; however, neither wild‐type receptor nor BFPP mutants gave any measurable recruitment upon Stachel stimulation, pointing different activation mechanisms for β‐arrestin involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell Institute, Ankara University, Ankara, Türkiye.
- Department of Biological Sciences, Middle East Technical University, Ankara, Türkiye.
- Department of Chemistry, Middle East Technical University, Ankara, Türkiye.
ORCID-Profile: Orkun Cevheroğlu, Salih Özçubukçu, Çağdaş D Son
Förderung
- Türkiye Bilimsel ve Teknolojik Araştirma Kurumu
- The Scientific and Technological Council of Turkey
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Cevheroğlu, O., Demir, N., Kesici, M. S., Özçubukçu, S., & Son, Ç. D. (2023). Downstream signalling of the disease‐associated mutations on GPR56/ADGRG1. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13873
Vancouver
Cevheroğlu O, Demir N, Kesici MS, Özçubukçu S, Son ÇD. Downstream signalling of the disease‐associated mutations on GPR56/ADGRG1. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13873
BibTeX
@article{Cevherolu2023,
author = {Cevheroğlu, Orkun and Demir, Nil and Kesici, Mehmet Seçkin and Özçubukçu, Salih and Son, Çağdaş D},
title = {Downstream signalling of the disease‐associated mutations on GPR56/ADGRG1},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
doi = {10.1111/bcpt.13873}
}
EUVIMED